Venator Capital Management’s OptimizeRx OPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-50,000
Closed -$1.89M 51
2022
Q1
$1.89M Sell
50,000
-69,700
-58% -$3.08M 1.03% 33
2021
Q4
$7.43M Sell
119,700
-82,300
-41% -$6.24M 3.08% 11
2021
Q3
$17.3M Sell
202,000
-15,500
-7% -$972K 8.21% 2
2021
Q2
$13.5M Buy
217,500
+11,500
+6% +$585K 4.57% 3
2021
Q1
$12.1M Sell
206,000
-51,448
-20% -$2.48M 4.1% 4
2020
Q4
$8.02M Sell
257,448
-55,452
-18% -$1.36M 3.4% 4
2020
Q3
$6.52M Buy
312,900
+217,900
+229% +$3.74M 3.47% 4
2020
Q2
$1.24M Buy
+95,000
New +$1.03M 0.82% 31
2020
Q1
Sell
-100,000
Closed -$1.03M 39
2019
Q4
$1.03M Sell
100,000
-101,800
-50% -$1.15M 0.99% 24
2019
Q3
$2.92M Sell
201,800
-12,200
-6% -$189K 2.53% 13
2019
Q2
$3.47M Buy
214,000
+5,521
+3% +$74.6K 3.37% 13
2019
Q1
$2.65M Sell
208,479
-19,362
-8% -$252K 2.75% 18
2018
Q4
$2.5M Sell
227,841
-8,078
-3% -$120K 2.9% 12
2018
Q3
$4.25M Sell
235,919
-11,642
-5% -$147K 2.13% 11
2018
Q2
$2.58M Buy
+247,561
New +$2.54M 1.76% 22

Other funds holding OPRX

Venator Capital Management's OPRX Position: Q2 2022 in Review

Venator Capital Management sold out of OptimizeRx (OPRX) in Q2 2022, closing a stake of 50,000 shares — an estimated $1.89M sold.

Venator Capital Management first reported a position in OPRX in Q2 2018 and held it in 15 quarters. The position peaked at $17.3M in Q3 2021. 146 funds tracked by Wall St. Rank hold OPRX as of Q2 2022.

  • Venator Capital Management reported no remaining OptimizeRx position as of Q2 2022 after selling out during the quarter.
  • Venator Capital Management sold 50,000 OptimizeRx shares in Q2 2022, an estimated $1.89M.
  • Venator Capital Management first reported a position in OptimizeRx in Q2 2018 and held it in 15 quarters.
  • Venator Capital Management's OptimizeRx position peaked at $17.3M in Q3 2021.
  • 146 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2022.

Based on Venator Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.